Rationale utilization of phospholipid excipients: a distinctive tool for progressing state of the art in research of emerging drug carriers

Koilpillai, Jebastin; Narayanasamy, Damodharan

doi:10.1080/08982104.2022.2069809

Cited by 9 publications

(1 citation statement)

References 268 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within the scope of the second strategy, our attention was drawn to liposomes that can encapsulate both hydrophilic and hydrophobic substrates [ 34 , 35 , 36 , 37 , 38 , 39 , 40 ] and allow for combination therapy of AD. In addition, it should be noted that liposomes have other advantages, including high biocompatibility, bioavailability, the ability to overcome biological barriers, and the protection of encapsulated substrates from premature degradation [ 41 , 42 , 43 , 44 ]. Of the three routes of administration of nanoformulated drugs for AD therapy—oral, transdermal, and intranasal—the latter is considered as the most promising [ 45 ].…”

Section: Introductionmentioning

confidence: 99%

Mitochondria-Targeted Delivery Strategy of Dual-Loaded Liposomes for Alzheimer’s Disease Therapy

Васильева

Gaynanova

Валеева

et al. 2023

IJMS

View full text Add to dashboard Cite

Liposomes modified with tetradecyltriphenylphosphonium bromide with dual loading of α-tocopherol and donepezil hydrochloride were successfully designed for intranasal administration. Physicochemical characteristics of cationic liposomes such as the hydrodynamic diameter, zeta potential, and polydispersity index were within the range from 105 to 115 nm, from +10 to +23 mV, and from 0.1 to 0.2, respectively. In vitro release curves of donepezil hydrochloride were analyzed using the Korsmeyer–Peppas, Higuchi, First-Order, and Zero-Order kinetic models. Nanocontainers modified with cationic surfactant statistically better penetrate into the mitochondria of rat motoneurons. Imaging of rat brain slices revealed the penetration of nanocarriers into the brain. Experiments on transgenic mice with an Alzheimer’s disease model (APP/PS1) demonstrated that the intranasal administration of liposomes within 21 days resulted in enhanced learning abilities and a reduction in the formation rate of Aβ plaques in the entorhinal cortex and hippocampus of the brain.

show abstract